The present disclosure relates generally to systems and methods for delivering neural therapy correlated with patient status.
Neurological stimulation or modulation systems have been developed to treat pain, movement disorders, functional disorders, spasticity and various other medical conditions. Implantable neurological stimulation systems may include an implantable pulse generator and one or more leads that deliver electrical pulses to neurological or muscle tissue. In many cases, a physician or caregiver may need to set a variety of stimulation parameters or programs for the patient, which may correspond to different postures, activities, or comfort levels that are assumed to be suitable for the patient. Generally, spinal cord stimulators provide the patient with many different stimulation programs, which are initially set up by the physician or caregiver with patient feedback. The initial setup typically occurs immediately after implant. The patient then uses a patient remote control to change between these programs when the patient's posture, activity, or comfort level has changed. However, in many cases, the preset stimulation levels established at implant may not be suitable for the patient due to slight changes in the lead after implant, scar tissue build-up around the lead after implant, or due to changes in pain patterns over time. These changes may require the patient to routinely adjust the stimulation settings, which requires office visits by the patient. Accordingly, there is a need for improved devices and techniques for customizing a patient's stimulation parameters and automatically adjusting stimulation levels for different patient needs.
Specific details of several embodiments of this disclosure are described below with reference to implantable spinal cord stimulators for stimulating neural structures, and methods for controllably stimulating a target neural site of a patient. As used herein, the terms “stimulating” and “stimulation” refer generally to signals applied to a patient to elicit a neural response. Unless otherwise specified, the signals may have an inhibitory or facilitatory effect on the target neural population. As used herein, the term “stimulator” applies generally to a device that generates and/or directs stimulation signals. Although selected embodiments are described below with respect to stimulating the dorsal column, dorsal root, dorsal root entry zone and/or other regions of the spinal column to control pain, the implantable stimulators may in some instances be used for stimulating other neurological structures, and/or other tissue (e.g., muscle tissue). Several embodiments can have configurations, components or procedures different than those described in this section, and other embodiments may eliminate particular components or procedures. A person of ordinary skill in the relevant art, therefore, will understand that the invention may have other embodiments with additional elements, and/or may have other embodiments without several of the features shown and described below with reference to
Several embodiments of the disclosure are directed to spinal cord stimulation devices (e.g., implantable pulse generators) that have an embedded control algorithm configured to monitor one or more physiological or physical signals from one or more sensors. The sensors can be inside or outside of the implantable device e.g. a spinal cord stimulation device. The sensors can include, for example, an accelerometer, a gyroscope, a blood pressure sensor, an impedance sensor, a thoracic impedance sensor, a heart rate monitor, a respiration rate monitor, a temperature sensor, and/or other suitable sensors. The control algorithm can have two phases—a learning phase and an automatic operation phase, as described in more detail below. In general terms, the control algorithm collects sensor data and correlates it with patient-selected signal delivery data during the learning phase. In the automatic operation phase, the control algorithm receives sensor data and directs the signal delivery based on the correlation established during the learning phase.
In a representative implementation, the spinal cord stimulation device is implanted into a patient. A physician, a device company representative, and/or other authorized personnel can program the spinal cord stimulation device by setting up one or more stimulation programs for the patient and allowing the patient to adjust stimulation parameters including, for example, an amplitude, a pulse width, a frequency, and/or other suitable parameters in the individual programs. Once the programs are established, the patient may have the ability to change only a subset of parameters in an individual program, e.g., only signal amplitude. Also, at the initial setup, the physician or the company representative can initialize the individual sensors with “normal” or expected values. The physician or the company representative can also set a confidence interval for the control algorithm, for example, from about 80% to about 99%, to indicate the end of the learning phase. The physician or the company representative can also set a delta change threshold for the individual sensors, e.g., using 5-10% of the signal average, for detecting abnormal operations of the spinal cord stimulation device and/or sensor inputs that are outside an expected range, as described in more detail below.
During an embodiment of the learning phase, the individual sensors are reset and normalized with initial values, and the spinal cord stimulation device is instructed to start learning by starting the control algorithm. In the learning phase, the spinal cord stimulation device (e.g., via the control algorithm) can continuously monitor the patient for a change of operation. The change of operation can include one or any combination of the following events: (1) a change in a stimulation program, (2) a change in a stimulation parameter, and/or (3) a delta change sensed by any of the sensors. The patient, the physician, or the company representative may cause the stimulation program and/or the parameters to change.
In response to the detected change of operation, the spinal cord stimulation device and/or the control algorithm can record the program settings, sensor readings, and/or other operational parameters associated with the change. For example, the control algorithm can record the time of day, the patient's body position, the patient's activity level, the currently active stimulation program and associated stimulation parameters, and/or other values. In certain embodiments, the sensor readings can be obtained from a gyroscope that senses a posture change, from an accelerometer that measures a change of motion, and/or from an active electrode on a lead body that measures impedance. With the recorded data, the spinal cord stimulation device and/or the control algorithm can build a database to associate the stimulation program and parameter settings with one or more sensor readings.
The database can be populated as the control algorithm learns, by recording the patient inputs. In the learning phase, the patient is in complete control of the spinal cord stimulation device. For example, any time the patient goes to sleep and uses “Program 2” (which has, e.g., a signal frequency of 80 Hz, a pulse width of 150 μsec, and an amplitude of 2.6 mA), the control algorithm populates the database with the time of day (e.g., nighttime), Program 2, and the parameter settings (e.g., frequency, pulse width and amplitude). Over a period of time (e.g., weeks, months, etc.), the spinal cord stimulation device can collect sufficient data to meet the preset confidence intervals and enter the automatic operation phase based on certain sensor readings.
During the automatic operation phase or automatic phase, the stimulation device uses the information in the populated database to set stimulation parameters, given inputs from one or more sensors. For example, the spinal cord stimulation device can enter the automatic phase for at least some body positions (e.g., standing, sitting, laying, etc., as determined by a gyroscope), the gross time of day (e.g., night (sleeping program), morning (active program), evening (watching TV program), etc,), and/or other suitable sensor readings. As a result, when the patient sits down, for example, the spinal cord stimulation device automatically changes the patient stimulation program and/or stimulation parameters to match the patient's preferred values. This change is based on information that the patient entered during the learning phase, rather than on the initial settings entered by the physician or company representative.
The length of time required to meet the confidence intervals may be patient-dependent. Factors that can influence the required amount of time may include the patient's level of use of the device, the number of therapy changes needed, and/or other factors which can vary for each patient depending on the patient's pain and activity level. In several embodiments, once the spinal cord stimulation device has met or exceeded the confidence intervals, the control algorithm enters the automatic phase. Not all conditions must be met before the device can enter the automatic phase. For example, if the spinal cord stimulation device reaches the preset confidence interval for the laying down body position during evening hours, then the spinal cord stimulation device can enter into the automatic phase for these conditions only, without affecting other conditions. The device can continue to operate in the learning phase or mode to collect data for other conditions. In the foregoing examples, identifiers such as “laying down” and “evening” are used for illustrative purposes. In actuality, the system can populate the database with raw and/or modified gyroscope data and clock data, without the need for identifiers.
When the spinal cord stimulation device enters the automatic phase, it can automatically change the stimulation program and/or stimulation parameters for the patient. In certain embodiments, the spinal cord stimulation device can alert the patient before automatically making an adjustment by displaying a message on a patient remote control, by producing a discrete vibration, and/or by utilizing other suitable means. In several embodiments, this alert feature may be removed over time or eliminated entirely.
The spinal cord stimulation device can continuously check for a change of sensor readings, a change in stimulation program, and/or a change in stimulation parameters that are outside the preset delta change thresholds. If such a change is detected and is outside expected limits, in certain embodiments, the spinal cord stimulation device can alert the patient that such a change has occurred. In certain cases, e.g. if the lead impedance is out of range indicating a lead failure or otherwise, the spinal cord stimulation system can notify the physician directly through the central database, by sending an automatic note (e.g. email, fax, voicemail or otherwise as appropriate) of the patient status change. For example, such a change can include a sensor value or a patient-input amplitude that is outside predefined limits, or a requested program change that was not encountered during the learning phase. In response, the patient can override this alert, and the control algorithm can record the event as a new database entry and start to learn more about this new setting, position, stimulation, etc. In other embodiments, the patient can turn off the stimulation therapy and see a physician. The physician can then troubleshoot and plan the next treatment for the patient. The spinal cord stimulation device can reenter the learning mode to learn the new programs, settings, etc. and switch to the automatic phase as described above.
The pulse generator 101 is configured to generate and transmit stimulation signals to the signal delivery device 112. In certain embodiments, the pulse generator 101 can include a logic processor interconnected with a computer-readable medium containing computer executable instructions, and further connected with input/output devices (e.g., wired or wireless transceivers), power management circuitry, and/or other suitable electrical components (not shown in
In a particular embodiment, the pulse generator 101 includes an embedded sensing element 126 in electrical communication with the logic processor of the pulse generator 101. The sensing element 126 can include at least one of a gyroscope, an accelerometer, a laser sensor, a pressure sensor, a temperature sensor, an impedance sensor, a heart rate monitor, a respiration rate monitor, a clock, and/or other suitable sensors for measuring the current status and/or physiological indicators of the patient. Even though the sensing element 126 is shown in
The therapy system 100 can also include a remote control 105 configured to communicate with and/or control the implantable pulse generator 101. As shown in
Optionally, in certain embodiments, the therapy system 100 can include a personal computer 110 coupled to the remote control 105 via a communication link 111 (e.g., a USB link, an Ethernet link, a Bluetooth link, etc.). In other embodiments, the personal computer 110 can be coupled to a network server 114 via a network connection 113 (e.g., an internet connection, an intranet connection, etc.) In yet other embodiments, the personal computer 110 and/or the network server 114 may be omitted. In further embodiments, the therapy system 100 can also include routers, switches, data storage centers, and/or other suitable network components.
After implanting the pulse generator 101, a caregiver (e.g., a physician or a pulse generator company representative) can first configure the pulse generator 101 with an initial set of operating programs and/or parameters using an external programmer (not shown). The caregiver may first configure the pulse generator 101 with an initial set of operating parameters for different patient status variables, such as for different pain areas or types and different patient body positions, patient physical activity levels, time of day, various physiological indicators of the patient, and/or other suitable patient status variables. The initial set of operating parameters can include frequencies, amplitudes, electrode selections for the signal delivery device 112, and/or other suitable parameters. For example, in one embodiment, the initial set of operating parameters can include a first amplitude for a first body position (e.g., standing) and a second amplitude for a second body position (e.g., lying down). In another embodiment, the initial set of operating parameters can also include a first electrode configuration that relates to a first pain area (e.g. the lower back) and a second electrode configuration that relates to a second pain area (e.g. the left leg). In other embodiments, the initial set of operating parameters can also include other operating parameters based on the time of day, physiological indicators of the patient, and/or other suitable process variables. According to the initial set of operating parameters programmed, the pulse generator 101 can apply therapy signals (e.g., electrical impulses) to the nerve fibers of the patient, such as to up-regulate (e.g., stimulate or facilitate) and/or down-regulate (e.g., block or inhibit) the neural response.
One operational difficulty associated with conventional implementations of the foregoing technique is that the initial set of parameters may not be suitable for the patient outside of a clinical setting. For example, without being bound by theory, it is believed that the signal delivery device 112 may shift when the patient is active (e.g., when the patient runs, walks, and/or engages in other activities) or when the patient changes from one body position to another (e.g., among positions such as standing, sitting, lying down, and/or others). The shifting of the signal delivery device 112 may render the applied therapy signals less effective for relieving pain, and/or may cause patient discomfort. It is also believed that the patient's perception of pain may be different at different activity levels. As a result, the initial set of parameters for the pulse generator 101 may not be effective to achieve and/or maintain treatment efficacy over an extended period of time and/or over the course of the patient's typical activities. The patient does have the option of adjusting the stimulation program and/or parameters with the remote control 105 (e.g., configured as a handheld device), within the preset values done at implant. However, the adjustment process using the remote control 105 may be cumbersome, restrictive, and/or time-consuming.
To overcome the above described operational difficulties, the presently disclosed therapy system 100 can be configured to (1) establish patient selections (e.g., preferences) during an initial period (e.g., a learning period); and (2) subsequently automatically adjust the stimulation parameters based, at least in part, on (a) the patient preferences learned during the initial period and (b) the current status (received through the sensors) of the patient. The patient preferences may include patient-selected or patient-preferred values of suitable stimulation parameters and may be referred to collectively as a preference baseline. Once the patient preferences are established, the pulse generator 101 can automatically adjust the stimulation parameters provided to the electrode array 103 in response to a change in the patient's activity level, body position and/or other variable to improve and/or maintain treatment efficacy, without further input from the patient.
During the initial (learning) period, the pulse generator 101 can continuously monitor the current status of the patient (via the sensing element 126) and/or the operation of the pulse generator 101 for a change. For example, in certain embodiments, the pulse generator 101 can sense a change when the patient changes at least one of a stimulation program (e.g., from a “day” program to a “night” program”), a stimulation parameter (e.g., an amplitude and/or a frequency of stimulation), and/or other suitable parameters. In certain embodiments, the patient can request or implement an increase or decrease in the amplitude of the applied therapy signals using the remote control 105, and the pulse generator 101 records the patient's change and/or any adjustments to the amplitude. In other embodiments, the pulse generator 101 can sense a change of operation under other suitable conditions.
When the pulse generator 101 senses a change of operation, the pulse generator 101 can record the values provided by other sensors. For example, the pulse generator 101 can record an indication of the current body position and/or orientation of the patient with a gyroscopic sensor to determine whether the patient is standing or lying down. The pulse generator 101 can sense the patient's current activity level with an accelerometer to determine a change in the movement of the patient and/or can sense the patient's blood pressure, thoracic impedance, and/or other suitable physiological indicators.
Based on the foregoing recorded measurements, the pulse generator 101 can establish the patient preferences. The pulse generator 101 can correlate at least one of the patient's indicated changes, the output of the pulse generator 101, with at least one of the current body position, the current activity level, and/or other physiological indicators of the patient. For example, in a particular embodiment, the pulse generator 101 can correlate the amplitude of the applied therapy signals with a patient's body position in two dimensions to generate a first preferred amplitude for the stimulation parameters when the patient is standing and a second preferred amplitude when the patient is lying down. In certain embodiments, each of the preferred amplitudes can be an arithmetic mean of multiple measurements corresponding to each body position, respectively. In other embodiments, the preferred amplitudes can be a median value, a geometric median value, a harmonic mean, a quadratic mean, a weighted mean (e.g., based on time of a day), and/or other values derived from the measurements.
In further embodiments, the pulse generator 101 can correlate several parameters of the applied stimulation parameters with the patient status in three, four, five, and/or other numbers of sensor inputs, which may correspond to patient activity levels, physiological parameters, and/or other suitable parameters. For example, the pulse generator 101 can correlate the stimulation parameters with certain values of both the body position and the activity level of the patient. As a result, the pulse generator 101 may calculate the preferred amplitude values as shown in the following table:
Even though particular values of the patient's position and activity level are used in the above example, in other examples, the pulse generator 101 can use other values of the patient's position (e.g., sitting) and/or activity level (e.g., walking, running, etc.). In yet further embodiments, the pulse generator 101 can use other patient parameters (e.g. thoracic impedance, heart rate, etc).
In certain embodiments, the initial (learning) period can be a predetermined time period (e.g., 2-5 weeks) set by the caregiver. In other embodiments, the initial period can be determined by the measurements recorded and stored in the pulse generator 101. For example, the initial period can expire when the derived first and second preferred amplitudes have reached a confidence level of at least 80% or another suitable value. In further embodiments, the patient and/or the caregiver can terminate the initial period irrespective of an elapsed time or the current confidence level of the first and second preferred amplitudes and reset the pulse generator 101 with most recent parameters and/or other suitable parameters.
Once the patient preferences are established (e.g., once the learning phase is complete), the pulse generator 101 can automatically adjust the stimulation parameters based on the sensed measurements. For example, when the pulse generator 101 receives an indication that the patient is currently standing, the pulse generator 101 can automatically adjust the stimulation parameters (e.g., an amplitude) based on a corresponding value of the preferred amplitude in the database for the standing position. The patient does not have to manually operate the remote control 105 in order to adjust the applied stimulation parameters. As a result, several embodiments of the therapy system 100 are less cumbersome, time-consuming, and/or restrictive to operate than are conventional techniques.
After the initial period expires, the pulse generator 101 can continue recording adjustment inputs from the patient regarding the operating parameters of the pulse generator 101, the current values of the generated stimulation parameters, and/or the current status of the patient as described above. The pulse generator 101 can periodically (e.g., weekly, biweekly, etc.) or continuously update (e.g., refine) the patient preferences based on these newly recorded measurements. In other embodiments, the process of further updating the preferences can be omitted.
In yet further embodiments, if the pulse generator 101 detects a large change in the patient's status, the pulse generator 101 can output an alarm to the patient and/or the caregiver indicating that an additional assessment is needed. In other examples, the patient and/or the caregiver can decide when to reestablish patient preferences.
Several embodiments of the therapy system 100 can improve treatment efficiency for the patient. Instead of estimating the applied therapy signals for each patient status, several embodiments of the therapy system 100 allow customization of the applied therapy signals based on previous measurements of the applied therapy signals, thus improving the efficacy of the treatment and/or reducing or eliminating the need for the patient to manually adjust stimulation settings. In certain embodiments, the therapy system 100 can also provide multiple stimulation levels to individually correspond to different patient statuses measured by the sensing element 126. For example, if the sensing element 126 indicates that the patient's motion exceeds a first threshold, a first stimulation level may be used. If the patient's motion exceeds a second threshold greater than the first threshold, a second stimulation level may be used. The caregiver and/or the patient may select any desired number of stimulation levels and/or thresholds of patient status.
Even though the therapy system 100 is described above as establishing the patient preferences via the implanted pulse generator 101, in other embodiments, this function can be performed with additional support from other devices. For example, the pulse generator 101 can transfer the recorded measurements to the optional personal computer 110 and/or the network server 114, and the personal computer 110 and/or the network server 114 can establish the patient preferences. In yet further embodiments, the patient may establish additional programs for the pulse generator 101, and the caregiver may have override capability over these additional programs.
The radio 118 can include a frequency modulator, an amplitude modulator, and/or other suitable circuitry for modulating inductive protocols. The processor 120 is configured to provide control signals to and receive data from the radio 118. In certain embodiments, the processor 120 can include a microprocessor, a field-programmable gate array, and/or other suitable logic components. In other embodiments, the processor 120 may also include a detector or a decoder with associated software and/or firmware to perform detection/decoding functions and process received signals. The memory 122 can include volatile and/or nonvolatile media (e.g., ROM, RAM, magnetic disk storage media, optical storage media, flash memory devices, and/or other suitable storage media). The memory 122 can be configured to store data received from, as well as instructions for, the processor 120. The input/output component 124 can include logic components (e.g., a MODEM driver) that receive and interpret input from the remote control 105 (
As shown
As described above, the patient preferences are established during the initial or learning period. The pulse generator 101 receives an initially collected sensor data set 157 representing patient measurements collected from the implantable pulse generator 101 (
The database module 151 is configured to organize the individual patient records stored in the memory 122 and provide the facilities for efficiently storing and accessing the collected sensor data sets 157 and 158 and patient data maintained in those records. Examples of suitable database schemes for storing the collected sensor data sets 157 and 158 in a patient record are described below with reference to
The processing module 156 processes the initially collected sensor data set 157 stored in the patient records to produce the patient preferences 152. The patient preferences 152 include a set of preference measurements 159 (e.g., body positions, the gross time of day, and/or other suitable sensor readings), which can be either directly measured or indirectly derived from patient information. The patient preferences 152 can be used to adjust the operating parameters for the pulse generator 101 and to monitor patient status on a continuous, ongoing basis.
On a periodic basis (or as needed or requested), the processing module 156 reassesses and updates the patient preferences 152. The database module 151 can receive the subsequently collected sensor data set 158 from the pulse generator 101 (
The analysis module 153 analyzes the subsequently collected sensor data set 158 stored in the patient records in the memory 122. The analysis module 153 monitors patient status and makes an automated determination in the form of a patient status indicator 154. Subsequently collected sensor data sets 158 are periodically received from pulse generator 101 and maintained by the database module 151 in the memory 122. Through the use of this collected information, the analysis module 153 can continuously follow the patient status and can recognize any trends in the collected information that might warrant medical intervention. The analytic operations performed by the analysis module 153 are described in more detail below with reference to
As shown in
The method 200 can also include establishing a preference or profile for the patient during an initial period (block 204) e.g., during a learning phase. The preference can include preference values for the operating parameters derived from recorded values for a particular patient status. For example, the preference may include a first preferred value for the stimulation amplitude when the patient is standing and a second preferred value when the patient is lying down. The preferences may also include baseline blood pressure, thoracic impedance, and/or other physiological indicators that give information about the patient status. Details of establishing the patient preferences are described in more detail below with reference to
The method 200 can further include using the data from the patient preferences to automatically adjust the therapy applied to patient, e.g., during an automated operation phase. This phase can include monitoring a patient status (block 206). In one embodiment, monitoring a patient status includes determining the current body position of the patient with a gyroscope and indicating whether the patient is standing or lying down. In other embodiments, monitoring a patient status can also include sensing the patient's current activity level, e.g., with an accelerometer. In further embodiments, monitoring a patient status can include measuring the blood pressure, and/or other suitable physiological parameters of the patient. In yet further embodiments, monitoring a patient status can include accepting a patient input using, for example, the remote control 105. Although such an input may not be required of the patient in light of the automatic operation of the system, the system can receive patient inputs that may override or facilitate the automatic operation.
The method 200 can also include determining whether a change in the patient status has exceeded a preset threshold (block 208), e.g., the delta threshold change, described previously. For example, the determination can be based on determining whether a subsequent measurement (e.g., lead impedance) exceeds a baseline value for a particular patient status (e.g., standing) by a certain percentage (e.g., 20%) or a preselected value (e.g., 4000 ohms). In other examples, the determination can also be based on other suitable criteria. The determination can be performed weekly, bi-weekly, at other periodic intervals, or on an as needed basis.
If the change in the patient status exceeds the preset threshold, the method 200 includes determining whether reprogramming is necessary (block 209). In one embodiment, the pulse generator 101 can provide a warning signal to the patient indicating that the caregiver should perform a checkup. The caregiver can then determine whether the signal delivery device 114 (
If the change in the patient status does not exceed the preset threshold, the method 200 can adjust the stimulation based on the measured patient status and the preferences in a closed-loop fashion (block 210). In one embodiment, adjusting the stimulation can include selecting a setpoint for an operating parameter (e.g., the stimulation amplitude) of the pulse generator 101 based on the preference value for a particular patient status. For example, the setpoint for the stimulation amplitude can be set to the preferred value or can be offset by a bias factor selected by the patient and/or the caregiver. In other embodiments, adjusting the stimulation can also include accepting input from the patient for increasing or decreasing the current stimulation level. In any of these embodiments, block 210 can include directing a change in the stimulation applied to the patient, based on the preference established in block 204.
The method 200 can also include updating the preferences after the initial period (block 212). For example, updating the preferences can include re-assimilating subsequent measurements for the patient status and/or values of the therapy signals. The method 200 can further include determining whether the process should continue (block 214). If so, the process reverts to monitoring the patient status at block 206. If not, the process ends. The updating can be performed weekly, bi-weekly, in other periodic intervals, or continuously.
The learning phase and/or the automatic operation phase can have other characteristics and/or other interrelationships in other embodiments. For example, in one such embodiment, the method 200 can include prioritizing the patient's preferences during the learning phase and storing this information for later use. In a particular example, the method 200 can include ordering the patient preferences by the frequency with which each preference is requested by the patient, and/or the duration that the preferred parameter value is in use. If the patient chooses “Program 4” most often when lying down, but then chooses “Program 2,” “Program 3” and “Program 1” in descending order, the method can include storing this information. Later (e.g., during the automatic operation phase), if the patient manually overrides the now-default selection of “Program 4,” the method can include presenting the patient with a preference-ordered list of next-best options, based on the information gathered during the learning phase. The options can be presented in a variety of suitable manners, including a textual list or a graphical representation. Accordingly, if the patient becomes dissatisfied with the program selected as a result of the learning phase, the method can automatically provide likely backup program selections, without requiring the patient to reconsider every possible program as an option. This can allow the patient to more quickly zero in on an effective new program if the existing program becomes less satisfactory, which may result e.g., if the implanted lead shifts or migrates.
In another embodiment, the method 200 can implement the foregoing preference tracking without necessarily making a clear distinction between a learning phase and an operation phase. Instead, both phases can be executed simultaneously. For example, the method 200 can include tracking patient preferences for a sliding period of time (e.g., one week or two weeks), and continuously updating the signal delivery parameters and patient prioritization of programs. When the patient manually overrides the automatically delivered program, the method can provide a prioritized list of alternate programs, as discussed above. The list can be weighted by the frequency with which each program is selected and/or the duration each program is in use, as discussed above. In other embodiments, the list can be weighted in other manners. For example, the most recent patient selection can receive the highest priority.
In still further embodiments, the foregoing meshed learning/operation phases can be implemented without tracking a prioritized list of patient preferences. Instead, the method can include continuously updating the applied signal delivery parameters based on feedback collected over a period of time (e.g., the past week, two weeks, or other period). If the patient does not frequently provide manual input or feedback, the signal delivery parameters can remain generally static. If the patient frequently updates the parameters, the method can adjust the signal delivery parameters accordingly, using an appropriate weighting scheme (e.g., greater weight given to the most recent patient request).
As described above, one or more impedance sensors can be used during the learning phase to correlate patient status (e.g., patient posture and/or activity level) with the patient's preferred stimulation parameters (e.g., therapy signal strength). The same impedance sensor or sensors can subsequently be used to identify changes in patient state, in response to which the system can automatically adjust the operating parameters with which the therapeutic signals are applied.
Beginning with
In still further embodiments, the impedance (e.g., overall impedance, resistance, and/or capacitance) can also be tracked as a function of time to identify patient status. For example,
In particular embodiments described above, the impedance characteristics are identified via contacts that also provide the therapy signal. The impedance characteristics can be determined from a therapy signal, or from a separate signal applied to the therapy contacts. In other embodiments, contacts that are not concurrently providing therapy, and/or other contacts (e.g., dedicated sensors), can be used to identify appropriate impedance values. Representative techniques for detecting impedance via implanted leads are disclosed in U.S. application Ser. No. 12/499,769, filed on Jul. 8, 2009 and incorporated herein by reference. In other embodiments, impedance measurements can be used in manners other than those described above. For example, the patient may have multiple leads or other arrangements in which impedance sensors are remote from each other, and the impedance profile information can be collected from the multiple leads/sensors. Profiles may be stored in a lookup table, profile bank or other suitable storage medium. The patient status can correspond to positions and/or activities other than those described above e.g., squatting, lying down on the patient's left side, lying down on the patient's right side, among others. In still further embodiments, the foregoing impedance profile information may be used in contexts other than spinal cord stimulation, e.g., peripheral nerve stimulation therapy, or cardiac therapy.
Several embodiments of the systems and methods described above with reference to
Several embodiments of the methods discussed above can improve patient comfort by allowing customization of the applied therapy signals. For example, the customization can include generating patient preferences based on previous measurements of the patient's preferences. The patient's comfort is further enhanced because several embodiments of the methods include detecting the patient's status and automatically adjusting a stimulation level of the applied therapy signals based on the patient preferences without patient input. The foregoing arrangement can reduce patient workload by automatically tracking the patient's stimulation preferences and automatically adjusting the applied stimulation parameters accordingly. In at least some embodiments, the process of adjusting the applied stimulation parameters based on patient preferences is performed at the patient's implanted device. This arrangement can reduce or eliminate the need for the patient to interact with any device other than the implant and the patient programmer.
From the foregoing, it will be appreciated that specific embodiments of the disclosure have been described herein for purposes of illustration, but that various modifications may be made without deviating from the disclosure. For example, in certain embodiments, the pulse generator 101 can include a plurality of integrated and remote sensing elements. Certain aspects of the disclosure described in the context of particular embodiments may be combined or eliminated in other embodiments. For example, in certain embodiments, the remote control 105 may be omitted, and the personal computer 110 may be operatively coupled to the antenna 108 for communicating with the pulse generator 101. Further, while advantages associated with certain embodiments have been described in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the disclosure. Accordingly, the invention can include other embodiments not explicitly described or shown herein.
The present application is a continuation of U.S. patent application Ser. No. 13/740,917, filed Jan. 14, 2013, issued as U.S. Pat. No. 9,199,083, which is a continuation of U.S. patent application Ser. No. 12/703,683, filed Feb. 10, 2010, and issued as U.S. Pat. No. 8,355,797, which claims priority to the following U.S. Provisional Applications, each of which is incorporated herein by reference: 61/151,464, filed Feb. 10, 2009, and 61/224,032, filed Jul. 8, 2009.
Number | Name | Date | Kind |
---|---|---|---|
4257429 | Dickhudt et al. | Mar 1981 | A |
4899750 | Ekwall | Feb 1990 | A |
5016635 | Graupe | May 1991 | A |
5031618 | Mullett | Jul 1991 | A |
5643330 | Holsheimer et al. | Jul 1997 | A |
5782884 | Stotts et al. | Jul 1998 | A |
6052624 | Mann | Apr 2000 | A |
6155267 | Nelson | Dec 2000 | A |
6236892 | Feler | May 2001 | B1 |
6308102 | Sieracki et al. | Oct 2001 | B1 |
6353762 | Baudino et al. | Mar 2002 | B1 |
6393325 | Mann et al. | May 2002 | B1 |
6440090 | Schallhorn | Aug 2002 | B1 |
6461357 | Sharkey et al. | Oct 2002 | B1 |
6574507 | Bonnet | Jun 2003 | B1 |
6622048 | Mann | Sep 2003 | B1 |
6659968 | McClure | Dec 2003 | B1 |
6740072 | Starkweather et al. | May 2004 | B2 |
6895280 | Meadows et al. | May 2005 | B2 |
6909917 | Woods et al. | Jun 2005 | B2 |
7024246 | Acosta et al. | Apr 2006 | B2 |
7123967 | Weinberg | Oct 2006 | B2 |
7142923 | North | Nov 2006 | B2 |
7174215 | Bradley | Feb 2007 | B2 |
7289851 | Gunderson et al. | Oct 2007 | B2 |
7317948 | King et al. | Jan 2008 | B1 |
7406351 | Wesselink | Jul 2008 | B2 |
7447545 | Heruth et al. | Nov 2008 | B2 |
7463927 | Chaouat | Dec 2008 | B1 |
7489970 | Lee et al. | Feb 2009 | B2 |
7555346 | Woods et al. | Jun 2009 | B1 |
7617002 | Goetz | Nov 2009 | B2 |
7819909 | Goetz et al. | Oct 2010 | B2 |
7853322 | Bourget et al. | Dec 2010 | B2 |
7872884 | Parramon et al. | Jan 2011 | B2 |
7957797 | Bourget et al. | Jun 2011 | B2 |
7957809 | Bourget | Jun 2011 | B2 |
8016776 | Bourget et al. | Sep 2011 | B2 |
8095220 | Lee et al. | Jan 2012 | B2 |
8116878 | Palmer | Feb 2012 | B1 |
8121703 | Palmer | Feb 2012 | B1 |
8355797 | Caparso | Jan 2013 | B2 |
8457759 | Parker et al. | Jun 2013 | B2 |
8498710 | Walker et al. | Jul 2013 | B2 |
8626312 | King et al. | Jan 2014 | B2 |
8712533 | Alataris et al. | Apr 2014 | B2 |
8712535 | Walker et al. | Apr 2014 | B2 |
9061154 | Parker et al. | Jun 2015 | B2 |
9295840 | Thacker et al. | Mar 2016 | B1 |
9399137 | Parker et al. | Jul 2016 | B2 |
20020068930 | Tasto et al. | Jun 2002 | A1 |
20020107553 | Hill et al. | Aug 2002 | A1 |
20030135248 | Stypulkowski | Jul 2003 | A1 |
20040015202 | Chandler et al. | Jan 2004 | A1 |
20040116978 | Bradley | Jun 2004 | A1 |
20040215286 | Stypulkowski | Oct 2004 | A1 |
20050060001 | Singhal et al. | Mar 2005 | A1 |
20050060007 | Goetz | Mar 2005 | A1 |
20050209645 | Heruth | Sep 2005 | A1 |
20060195159 | Bradley et al. | Aug 2006 | A1 |
20060247732 | Wesselink | Nov 2006 | A1 |
20060253174 | King | Nov 2006 | A1 |
20060259079 | King et al. | Nov 2006 | A1 |
20070013758 | Lim et al. | Jan 2007 | A1 |
20070073357 | Rooney et al. | Mar 2007 | A1 |
20070100378 | Maschino | May 2007 | A1 |
20070135868 | Shi et al. | Jun 2007 | A1 |
20070150029 | Bourget et al. | Jun 2007 | A1 |
20070156207 | Kothandaraman et al. | Jul 2007 | A1 |
20070179579 | Feler et al. | Aug 2007 | A1 |
20070208394 | King et al. | Sep 2007 | A1 |
20070213789 | Nolan et al. | Sep 2007 | A1 |
20070249968 | Miesel et al. | Oct 2007 | A1 |
20070250121 | Miesel et al. | Oct 2007 | A1 |
20070255118 | Miesel et al. | Nov 2007 | A1 |
20070265681 | Gerber et al. | Nov 2007 | A1 |
20080015657 | Haefner | Jan 2008 | A1 |
20080046036 | King et al. | Feb 2008 | A1 |
20080064980 | Lee et al. | Mar 2008 | A1 |
20080071325 | Bradley | Mar 2008 | A1 |
20080109050 | John | May 2008 | A1 |
20080154340 | Goetz et al. | Jun 2008 | A1 |
20080188909 | Bradley | Aug 2008 | A1 |
20080215118 | Goetz et al. | Sep 2008 | A1 |
20080269843 | Gerber et al. | Oct 2008 | A1 |
20080281381 | Gerber et al. | Nov 2008 | A1 |
20080319511 | Pless | Dec 2008 | A1 |
20090125079 | Armstrong et al. | May 2009 | A1 |
20090149917 | Whitehurst et al. | Jun 2009 | A1 |
20090204173 | Fang et al. | Aug 2009 | A1 |
20090264956 | Rise et al. | Oct 2009 | A1 |
20090264957 | Giftakis et al. | Oct 2009 | A1 |
20090264967 | Giftakis et al. | Oct 2009 | A1 |
20090306746 | Blischak | Dec 2009 | A1 |
20100010432 | Skelton | Jan 2010 | A1 |
20100049280 | Goetz | Feb 2010 | A1 |
20100057162 | Moffitt et al. | Mar 2010 | A1 |
20100069993 | Greenspan | Mar 2010 | A1 |
20100121408 | Imran et al. | May 2010 | A1 |
20100121409 | Kothandaraman et al. | May 2010 | A1 |
20100185256 | Hulvershorn | Jul 2010 | A1 |
20100274314 | Alataris et al. | Oct 2010 | A1 |
20100274317 | Parker et al. | Oct 2010 | A1 |
20110009927 | Parker et al. | Jan 2011 | A1 |
20110040351 | Butson et al. | Feb 2011 | A1 |
20110071593 | Parker et al. | Mar 2011 | A1 |
20110093051 | Davis et al. | Apr 2011 | A1 |
20110184488 | De Ridder | Jul 2011 | A1 |
20110190847 | King et al. | Aug 2011 | A1 |
20120083857 | Bradley et al. | Apr 2012 | A1 |
20120116476 | Kothandaraman | May 2012 | A1 |
20120130448 | Woods et al. | May 2012 | A1 |
20120172946 | Alataris et al. | Jul 2012 | A1 |
20120253422 | Thacker et al. | Oct 2012 | A1 |
20120265268 | Blum et al. | Oct 2012 | A1 |
20120265271 | Goetz | Oct 2012 | A1 |
20130023950 | Gauthier | Jan 2013 | A1 |
20130060302 | Polefko et al. | Mar 2013 | A1 |
20130066411 | Thacker et al. | Mar 2013 | A1 |
20130116752 | Parker et al. | May 2013 | A1 |
20130261694 | Caparso et al. | Oct 2013 | A1 |
20130310892 | Parker et al. | Nov 2013 | A1 |
20140081349 | Lee et al. | Mar 2014 | A1 |
20140330338 | Walker et al. | Nov 2014 | A1 |
20150217113 | Walker et al. | Aug 2015 | A1 |
Number | Date | Country |
---|---|---|
08503648 | Apr 1996 | JP |
20020527159 | Aug 2002 | JP |
2006502811 | Jan 2006 | JP |
2006212458 | Aug 2006 | JP |
2008526299 | Jul 2008 | JP |
2008534168 | Aug 2008 | JP |
2009519771 | May 2009 | JP |
WO-2006119046 | Nov 2006 | WO |
WO-2007149018 | Dec 2007 | WO |
WO-2008142402 | Nov 2008 | WO |
Entry |
---|
European Search Report for European Patent Application No. 14151730.0, Applicant: Nevro Corporation, mailed Jul. 9, 2014, 6 pages. |
Hayt et al., “Engine Circuit Analysis,” McGraw-Hill Book Company, Fourth Edition, 1986, 18 pages. |
International Search Report and Written Opinion, International Application No. PCT/US2010/023787, Applicant: Nevro Corporation, European Patent Office, mailed Jun. 2, 2010, 16 pages. |
Keuchmann C et al., “853 Could Automatic Position Adaptive Stimulation be Useful in Spinal Cord Stimulation,” Abstract, Medtronic, Inc., undated, 1 page. |
Notice of Opposition to a European Patent for European Patent No. 2043589, Proprietor of the Patent: Nevro Corporation; Opponent: Boston Scientific Neuromodulation Corporation, Oct. 22, 2014, 32 pages. |
Notice of Opposition to a European Patent for European Patent No. 2043589, Proprietor of the Patent: Nevro Corporation, Opponent: Medtronic, Inc., Oct. 13, 2014, 20 pages. |
Notice of Opposition to a European Patent, Argument and Facts, for European Patent No. 2459271, Proprietor of the Patent: Nevro Corporation; Opponent: Boston Scientific Neuromodulation Corporation, Jan. 20, 2016, 22 pages. |
U.S. Appl. No. 14/161,512, filed Jan. 22, 2014, Thacker et al. |
U.S. Appl. No. 14/161,592, filed Jan. 22, 2014, Thacker et al. |
U.S. Appl. No. 15/017,512, filed Feb. 5, 2016, Thacker et al. |
U.S. Appl. No. 15/057,913, filed Mar. 1, 2016, Bradley et al. |
U.S. Appl. No. 15/192,931, filed Jun. 24, 2016, Walker et al. |
U.S. Appl. No. 15/208,542, filed Jul. 12, 2016, Parker et al. |
Notice of Opposition to a European Patent for European Patent No. 2403589, Proprietor of the Patent: Nevro Corporation; Opponent: Boston Scientific Neuromodulation Corporation, Oct. 22, 2014, 32 pages. |
Notice of Opposition to a European Patent for European Patent No. 2403589, Proprietor of the Patent: Nevro Corporation, Opponent: Medtronic, Inc., Oct. 13, 2014, 20 pages. |
Nevro Response to Notice of Oppositions of Boston Scientific and Medtronic, Inc., for European Patent No. 2403589, mailed Jun. 1, 2015, 10 pages. |
Opponents: Boston Scientific Response to Proprietor's Response to Notice of Opposition for European Patent No. 2403589, mailed Jun. 27, 2016, 21 pages. |
Opponents: Medtronic, Inc., Additional Observations and Submissions in view of the Oral Proceedings for Opposition for European Patent No. 2403589, mailed Jan. 20, 2017, 29 pages. |
Number | Date | Country | |
---|---|---|---|
20160144187 A1 | May 2016 | US |
Number | Date | Country | |
---|---|---|---|
61151464 | Feb 2009 | US | |
61224032 | Jul 2009 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13740917 | Jan 2013 | US |
Child | 14944069 | US | |
Parent | 12703683 | Feb 2010 | US |
Child | 13740917 | US |